Dosing & Uses
AdultPediatric
Amyotrophic Lateral Sclerosis
Pending FDA approval for amyotrophic lateral sclerosis (ALS)
Safety and efficacy not established
Next:
Pharmacology
Mechanism of Action
Oral stem cell factor (SCF) receptor tyrosine kinase inhibitor; targets mast cells and macrophages by inhibiting a number of protein kinases within these cells
Masitinib targets neurotoxic aberrant glial cells (resident macrophages in the brain) via CSF1R inhibition, thereby providing a neuroprotective effect and slowing down neurodegeneration
Previous
Next:
Images
No images available for this drug.
Previous
Next:
Medscape prescription drug monographs are based on FDA-approved labeling information, unless otherwise noted, combined with additional data derived from primary medical literature.
